Diabétologie
Le cagrilintide, analogue lent de l’amyline, futur médicament de l’obésité ?
Jean-Louis SCHLIENGER, Strasbourg
Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomized, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial...